TGF-β is the sole cytokine that had its role as a biomarker of response to the treatment evaluated in a Phase II clinical trial examining the efficacy of ICIs among participants with advanced HCC [57]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.